Investigación

Inicio » Profesionales sanitarios » Investigación

Investigación sobre vacunas

desarrollada por FUNCEI

Síntesis de estudios científicos publicados

Se agrupan por enfermedad, en orden alfabético y luego por fecha.

Cólera y vacuna

  • Cookson, S.T., Stamboulian, D., Demonte, J., Quero, L., Martinez de Arquiza, C., Aleman, A., Lepetic, A. y Levine, M.M. (1997): “A cost-benefit analysis of programmatic use of CVD 103-HgR live oral cholera vaccine in a high-risk population”. Int J Epidemiol., 26(1), 212-9. PMID: 9126522 DOI: 10.1093/ije/26.1.212

Hepatitis y vacuna

  • Lepetic, A., Biscayart, C., Seigelchifer, M., Arduino, R. y Stamboulian, D. (2003): “Persistence of immunity and seroprotection 4 years after a primary vaccination schedule with a Hansenula polymorpha recombinant hepatitis B vaccine”. Vaccine, 21(27-30), 4481-5. DOI: 10.1016/s0264-410x(03)00306-2. PMID: 14505931.

Influenza y vacuna antigripal

  • Stamboulian D, Bonvehí PE, Nacinovich FM, Rüttimann RW. Immunization against influenza in the elderly: the Argentinian experience, 1993-1997. Vaccine. 1999 Jul 30;17 Suppl 1:S53-6. PMID: 10471181 DOI: 10.1016/s0264-410x(99)00106-1

  • Dayan, G.H., Nguyen V.H., Debbag, R., Gómez, R. y Wood, S.C. (2001): “Cost-effectiveness of influenza vaccination in high-risk children in Argentina”. Vaccine, 19(30), 4204-13. PMID: 11457546 DOI: 10.1016/s0264-410x(01)00160-8

  • Vázquez, H., Dignani, C., Bologna, R., Rojas, M. and Stamboulian, D. (2010), Reflections on the Pandemic Influenza A (H1N1) Experience in Argentina. World Medical & Health Policy, 2: 37-41. https://doi.org/10.2202/1948-4682.1053.

  • Eizenberg, P., Booy, R., Naser, N., Mason, G., Stamboulian, D. y Weber, F. (2011): “Acceptance of Intanza® 9 mug Intradermal Influenza Vaccine in Routine Clinical Practice in Australia and Argentina”. Adv Ther., 28(8), 640-649. DOI: 10.1128/CMR.00097-12

  • Tregnaghi, M., Stamboulian, D., Vanadía, P. C., Tregnaghi, JP., Calvari, M., Fragapane, E., Casula, D., Pellegrini, M. y Groth, N. (2012): “Immunogenicity, Safety, and Tolerability of Two Trivalent Subunit Inactivated Influenza Vaccines: A Phase III, Observer-Blind, Randomized, Controlled Multicenter Study”. Viral Immunology, 25(3), 216-225. DOI: https://doi.org/10.1089/vim.2011.0063, PMID: 22691101.

Meningococo y vacunas

  • Stamboulian, D., Lopardo, G., López, P., Cortes-Barbosa, C., Valencia, A., Bedell, L., Karsten, A. y Dull, P.M. (2010): “Safety and immunogenicity of an investigational quadrivalent meningococcal CRM197 conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America”. International Journal of Infectious Diseases, 14(10), e868-75. DOI: 10.1016/j.ijid.2010.03.017.

  • Tregnaghi, M., López, P., Stamboulian, D., Graña, G., Odrljin, T., Bedell, L., Dull, P.M. (2014): “Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers”. Int J Infect Dis, 26C, 22-30. https://doi.org/10.1016/j.ijid.2014.03.1390

Neumonía adquirida en la comunidad y vacunas

Varicela y vacuna

  • Fridman, D., Monti, A., Bonnet, M. C., Armoni, J. y Stamboulian, D. (2011). “Safety of a second dose of varicella vaccine administered at 4 to 6 years of age in healthy children in Argentina”. Human Vaccines, 7(10), 1-6. PMID: 21989288 PMCID: PMC3256328 DOI: 10.4161/hv.7.10.17816
Ver  FUNCEI Investigaciones

Compartir

Última actualización 12 de octubre, 2021